Seek Returns logo

ASND vs. GKOS: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ASND and GKOS, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ASND dominates in value with a market cap of 9.55 billion USD, eclipsing GKOS’s 5.42 billion USD by roughly 1.76×.

GKOS carries a higher beta at 0.83, indicating it’s more sensitive to market moves, while ASND remains steadier at 0.40.

ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while GKOS remains a standard domestic listing.

SymbolASNDGKOS
Company NameAscendis Pharma A/SGlaukos Corporation
CountryDKUS
SectorHealthcareHealthcare
IndustryBiotechnologyMedical - Devices
CEOMr. Jan Moller MikkelsenMr. Thomas William Burns
Price158.1 USD94.82 USD
Market Cap9.55 billion USD5.42 billion USD
Beta0.400.83
ExchangeNASDAQNYSE
IPO DateJanuary 28, 2015June 25, 2015
ADRYesNo

Performance Comparison

This chart compares the performance of ASND and GKOS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ASND and GKOS based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • Neither ASND nor GKOS turned a profit—both carry negative P/E ratios of -24.55 and -43.42, underscoring continued losses that pressure their valuations.
  • Analysts assign negative forward PEG ratios to both ASND (-2.23) and GKOS (-2.44), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
  • ASND has a negative P/B ratio of -44.20, indicating its liabilities exceed assets (negative equity). GKOS, with a P/B of 7.03, maintains positive shareholder equity.
  • ASND and GKOS both consumed more free cash flow than they generated last year—P/FCF of -27.43 and -101.77, respectively—highlighting persistent liquidity pressure.
SymbolASNDGKOS
Price-to-Earnings Ratio (P/E, TTM)-24.55-43.42
Forward PEG Ratio (TTM)-2.23-2.44
Price-to-Sales Ratio (P/S, TTM)22.8913.39
Price-to-Book Ratio (P/B, TTM)-44.207.03
Price-to-Free Cash Flow Ratio (P/FCF, TTM)-27.43-101.77
EV-to-EBITDA (TTM)-35.74-67.34
EV-to-Sales (TTM)23.7813.37
EV-to-Free Cash Flow (TTM)-28.50-101.60

Dividend Comparison

Neither ASND nor GKOS currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.

SymbolASNDGKOS
Dividend Yield (TTM)0.00%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ASND and GKOS, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas GKOS at 5.62 maintains a comfortable buffer of liquid assets.
  • ASND has negative equity (debt-to-equity ratio -4.46), an unusual warning sign, while GKOS at 0.14 maintains a conventional debt-to-equity balance.
  • Both ASND and GKOS report negative interest coverage ratios (-3.72, -13.09), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
SymbolASNDGKOS
Current Ratio (TTM)1.046.49
Quick Ratio (TTM)0.715.62
Debt-to-Equity Ratio (TTM)-4.460.14
Debt-to-Assets Ratio (TTM)0.800.11
Interest Coverage Ratio (TTM)-3.72-13.09